Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 9/20 | 0.41 |
| ▸ | PPARA | Q07869 | 7/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498481 | 0.94 | POLB (0.44) | CETPPPARDPPARAPPARGMAPT | |
| SCHEMBL4515600 | 0.93 | CETP (0.46) | CETPPPARDPPARAPPARGMAPT | |
| SCHEMBL4522410 | 0.92 | PPARD (0.44) | CETPPPARDPPARAPPARGMAPT | |
| SCHEMBL4521400 | 0.91 | CETP (0.44) | CETPPPARDPPARAMAPTLMNA | |
| SCHEMBL4517041 | 0.91 | CETP (0.41) | CETPPPARDPPARAPPARGMAPT | |
| SCHEMBL4501707 | 0.91 | CETP (0.44) | CETPPPARDPPARAMAPTTP53 | |
| SCHEMBL4522726 | 0.89 | PPARD (0.56) | CETPPPARDPPARAPPARG | |
| SCHEMBL4511561 | 0.89 | CETP (0.43) | CETPPPARDPPARAPPARGMAPT | |
| SCHEMBL4515584 | 0.88 | PPARD (0.48) | CETPPPARDPPARAPPARGBTK | |
| SCHEMBL4523286 | 0.88 | CACNA1G (0.42) | CETPMAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203908-A1 | Activator for Peroxisome Proliferator-Activated Receptor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1897872-A1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Nippon Chemiphar Co., Ltd. (JP) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203908-A1 | Activator for Peroxisome Proliferator-Activated Receptor | PPARA, PPARG, PPARD | CETP 1172/4885PPARD 3/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.